[1]谭子跃.干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响[J].医学信息,2023,36(20):137-140.[doi:10.3969/j.issn.1006-1959.2023.20.027]
　TAN Zi-yue.Effect of Interferon Combined with Entecavir in the Treatment of Patients with Hepatitis B and its Effect on Liver Function[J].Journal of Medical Information,2023,36(20):137-140.[doi:10.3969/j.issn.1006-1959.2023.20.027]
点击复制

干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年20期
页码:
137-140
栏目:
论著
出版日期:
2023-10-15

文章信息/Info

Title:
Effect of Interferon Combined with Entecavir in the Treatment of Patients with Hepatitis B and its Effect on Liver Function
文章编号:
1006-1959（2023）20-0137-04
作者:
谭子跃
（余干县人民医院门诊二楼，江西 余干 335100）
Author(s):
TAN Zi-yue
(The Second Floor of the Outpatient Department of Yugan County People’s Hospital,Yugan 335100,Jiangxi,China)
关键词:
干扰素; 恩替卡韦; 乙型病毒性肝炎; 肝功能
Keywords:
Interferon; Entecavir; Hepatitis B; Liver function
分类号:
R575.1
DOI:
10.3969/j.issn.1006-1959.2023.20.027
文献标志码:
A
摘要:
目的 研究干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对肝功能的影响。方法 选取2020年1月-2022年9月在我院诊治的58例乙型病毒性肝炎患者为研究对象，采用随机数字表法分为对照组（n=29）和观察组（n=29），对照组采用恩替卡韦治疗，观察组在对照组基础上给予干扰素治疗，比较两组临床疗效、乙肝病毒基因（HBV－DNA）转阴率、肝功能指标［谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）]、并发症发生率、生活质量水平及不良反应发生率。结果 观察组治疗总有效率（93.10%）高于对照组（79.31%）（P＜0.05）；观察组HBV－DNA转阴率（75.86%）高于对照组（51.72%）（P＜0.05）；两组治疗后ALT、AST均低于治疗前，TBIL均高于治疗前，且观察组ALT、AST低于对照组，TBIL高于对照组（P＜0.05）；观察组并发症发生率为10.34%，低于对照组的24.14%（P＜0.05）；两组治疗后生活质量水平高于治疗前，且观察组高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 干扰素合并恩替卡韦治疗乙型病毒性肝炎具有确切的疗效，可提高治疗效果，改善肝功能，提升HBV-DNA转阴率，降低并发症发生率，且无严重不良反应，具有良好的有效性、安全性，值得临床应用。
Abstract:
Objective To study the efficacy of interferon combined with entecavir in the treatment of patients with hepatitis B and its effect on liver function.Methods A total of 58 patients with hepatitis B diagnosed and treated in our hospital from January 2020 to September 2022 were selected as the research objects. They were divided into control group (n=29) and observation group (n=29) by random number table method. The control group was treated with entecavir, and the observation group was treated with interferon on the basis of the control group. The clinical efficacy, negative conversion rate of hepatitis B virus gene (HBV-DNA), liver function indexes [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL)], incidence of complications, quality of life level and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group (93.10%) was higher than that in the control group (79.31%) (P<0.05). The negative conversion rate of HBV-DNA in the observation group (75.86%) was higher than that in the control group (51.72%) (P<0.05). After treatment, ALT and AST in the two groups were lower than those before treatment, TBIL was higher than that before treatment, and ALT and AST in the observation group were lower than those in the control group, TBIL was higher than that in the control group (P<0.05). The incidence of complications in the observation group was 10.34 %, which was lower than 24.14 % in the control group (P<0.05). The quality of life of the two groups after treatment was higher than that before treatment, and that of the observation group was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Interferon combined with entecavir has a definite effect in the treatment of viral hepatitis B, which can improve the therapeutic effect, improve liver function, increase HBV-DNA negative conversion rate, reduce the incidence of complications, and has no serious adverse reactions. It has good efficacy and safety and is worthy of clinical application.

参考文献/References:

[1]黄丽华,谭礼让,何妍梅.聚乙二醇干扰素α-2a联合替诺福韦治疗HBV/HCV重叠感染患者的疗效及影响因素分析[J].国际消化病杂志,201,39(6):394-398.[2]宗杰,周建飞.安络化纤丸联合聚乙二醇干扰素α-2a对慢性乙肝肝纤维化患者肝功能及肝纤维化的影响[J].医学临床研究,2019,36(4):771-773.[3]嵇玮嘉,颜学兵.聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较[J].临床肝胆病杂志,2017,35(2):309-314.[4]Cao WH,Li MH,Zhang L,et al.The characteristics of natural killer cells in chronic hepatitis B patients who received PEGylated-interferon versus entecavir therapy[J]. Biomed Res Int,2021,2021:2178-218.[5]王成军,邱邦东.恩替卡韦联合聚乙二醇干扰素α2a治疗乙型病毒性肝炎的效果及对患者血清 YKL-40、CEA水平的影响[J].海南医学,2019,30(20):2608-2611.[6]王贵强,王福生,庄辉,等.慢性乙型肝炎防治指南（2019年版）[J].中华实验和临床感染病杂志,2019,13(6):441-466.[7]彭菁,焦方舟,李汛,等.替诺福韦与恩替卡韦治疗HBeAg阳性慢性乙型病毒性肝炎患者临床短期疗效[J].武汉大学学报,2019,40(4):640-644.[8]中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎临床治愈（功能性治愈）专家共识[J].临床肝胆病杂志,2019,35(8):1693-1701.[9]王叶,卢秉久.逍遥散加减联合恩替卡韦分散片治疗肝郁脾虚型慢性乙型病毒性肝炎临床观察[J].河北中医,2019,11(10):1530-1531,1544.[10]Hu P,Shang J,Zhang WH,et al.HBsAg Loss with Peg interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog :new switch study[J].J Clin Transl Hepatol,2018,6(1):25-34.[11]刘楷,沈妍希,凌宁,等.聚乙二醇干扰素α-2a治疗慢性乙型肝炎过程中外周血γδT细胞的变化及其临床意义[J].中华肝脏病杂志,2018,26(5):365-370. [12]Tsai KN,Kuo CF,Ou JJ.Mechanisms of hepatitis B virus persistence[J].Trends Microbiol,2018,26(1):33-42.[13]王祖煜,刘熠赫,张芮.2004-2013年中国乙型病毒性肝炎的流行病学特征研究[J].中国全科医学,2017,20(23):2879-2883.[14]刘佳.慢性乙型肝炎病毒感染对外周血单个核细胞中凋亡分子表达的影响及其与免疫功能的相关性[J].安徽医药,2017,21(10):1830-1832. [15]Kim SE.Quantitative hepatitis B surface antigen predicts the antivi ral response and hepato cellular carcinoma development in patients with chronic hepatitis B[J].Korean J Intern Med,2017,32(4):631-633.[16]张弦,蒋伟,甘建和.恩替卡韦治疗慢性乙型肝炎的疗效及其对外周血调节性T细胞水平的影响[J].山东医药,2017,56(34):42-44.[17]陈东海.聚乙二醇干扰素联合恩替卡韦治疗慢性乙型肝炎的效果[J].河南医学研究,2019,28(2):294-295.[18]王哲.替诺福韦联合干扰素α对慢性乙型肝炎患者肝功能及血清HBV-DNA转阴率的影响[J].检验医学与临床,2019,16(9):1218-1221.[19]楚玉兰,顾洪立,兰继.慢性乙型肝炎及后期肝病患者外周血T淋巴细胞亚群标志的研究[J].实用预防医学,2017,23(7):873-876.[20]张春,陈祖涛,吴建成,等.恩替卡韦联合聚乙二醇化干扰素α－2a治疗 HBeAg阳性慢性乙型肝炎的临床观察[J].苏州大学学报,2010,30(1):183-184.

相似文献/References:

[1]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(20):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
[2]尹静华.核黄素磷酸钠联合干扰素治疗小儿疱疹性咽峡炎的 疗效观察[J].医学信息,2018,31(10):138.[doi:10.3969/j.issn.1006-1959.2018.10.046]
　YIN Jing-hua.Therapeutic Effect of Riboflavin Sodium Phosphate Combined with Interferon on Pediatric Herpangina[J].Journal of Medical Information,2018,31(20):138.[doi:10.3969/j.issn.1006-1959.2018.10.046]
[3]姜海燕.恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响[J].医学信息,2022,35(09):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
　JIANG Hai-yan.Effect of Entecavir Combined with Compound Glycyrrhizin on Liver Function and Serum Levels of HA, Ⅳ-C and PC-Ⅲ in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(20):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
[4]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Journal of Medical Information,2018,31(20):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Journal of Medical Information,2019,32(20):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[6]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Journal of Medical Information,2019,32(20):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[7]李嘉丽,温 静,周 甦,等.主动随访督导乙型肝炎肝硬化长期依从抗病毒的效果[J].医学信息,2019,32(10):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
　LI Jia-li,WEN Jing,ZHOU Su,et al.Active Follow-up to Monitor the Long-term Compliance with Antiviral Effects of Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(20):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
[8]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Journal of Medical Information,2019,32(20):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
[9]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
　PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(20):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[10]周 煜.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响[J].医学信息,2019,32(22):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
　ZHOU Yu.Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(20):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]

更新日期/Last Update: 1900-01-01